Publications
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
Published: 11 Oct. 2016
Ann Oncol (2016) 27 (suppl_6): 378P
Background: ABTL0812 is an anticancer agent in clinical development with a novel mechanism of action. It inhibits the Akt/mTOR axis after binding to PPARs and subsequent induction of TRIB3, a pseudokinase that acts as a negative regulator of Akt. Preclinical studies have shown high efficacy in different tumor types including NSCLC, endometrial cancer, pancreatic cancer and neuroblastoma. ABTL0812 exhibits, efficacy in resistant models and synergy with chemotherapy while maintaining extremely low toxicity.
Methods: A phase Ib clinical trial with a 3 + 3 escalation design and an expansion phase was performed in patients with advanced solid tumors. Safety and tolerability were the main objectives of the trial. ABTL0812 pharmacokinetics (PK) was determined and the ratio between phosphorylated Akt and total Akt (pAkt/Akt) levels in...
LATEST NEWS
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + infoPress Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + infoPress Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + infoPress Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + infoPress Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + infoPress Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + infoPress Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + infoPress Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + infoPress Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info